实例探究 > Oxford Biomedica and Antha: Multifactorial Optimisation of a Lentiviral Vector Transfection/Transduction System

Oxford Biomedica and Antha: Multifactorial Optimisation of a Lentiviral Vector Transfection/Transduction System

公司规模
1,000+
地区
  • Europe
国家
  • United Kingdom
产品
  • LentiVector® platform
  • Antha
  • Synthace
  • Gilson PIPETMAX®
技术栈
  • Design of Experiments (DoE)
  • Liquid Handling Automation
  • In Silico Simulation
实施规模
  • Departmental Deployment
影响指标
  • Cost Savings
  • Innovation Output
  • Productivity Improvements
技术
  • 分析与建模 - 预测分析
  • 应用基础设施与中间件 - 数据交换与集成
  • 功能应用 - 远程监控系统
适用行业
  • 医疗保健和医院
  • 生命科学
适用功能
  • 产品研发
  • 质量保证
用例
  • 质量预测分析
  • 过程控制与优化
  • 远程控制
服务
  • 软件设计与工程服务
  • 系统集成
关于客户
Oxford Biomedica is a world leader and pioneer in lentiviral vector research, manufacture, and clinical development. With over 20 years of experience in gene and cell therapy, they were the first organization to treat humans with in vivo lentiviral-based vectors. Their unique LentiVector® platform has led to a valuable portfolio of gene and cell therapy product candidates for oncological, ophthalmological, and CNS indications. In 2018, they started working with Antha to automate highly complex experiments, choosing Synthace and Antha for their rapid and flexible design and in silico simulation capabilities.
挑战
Oxford Biomedica faced the challenge of improving the efficiency and robustness of their in-house lentiviral vector production. The complexity of the biological system required a multifactorial experimental approach, which would have been very challenging to execute manually due to the number of experimental runs and the complexity of the design. Additionally, the high cost of therapy and the global demand for quality lentiviral vectors created a 'vector crunch' in the sector, necessitating the optimization of product quality, developability, and vector titres.
解决方案
Oxford Biomedica employed Antha in their R&D labs to optimize their transfection reagent mixes. Antha allowed them to save up to 40 hours on experimental planning and execution by automating the process through a liquid handling platform. The initial optimization identified transfection conditions that achieved a 3 to 10-fold increase in vector titre upon transduction, with an 81% reduction in pure error. Using Antha's DoE suite, they could rapidly define an automated liquid handling protocol, saving 95-98% of the time compared to manual methods. Antha's features also provided a 22% saving in liquid handling actions and a 32% saving in pipette tip usage.
运营影响
  • Antha allowed Oxford Biomedica to automate complex multifactorial experiments, saving significant time and resources.
  • The optimization process identified key factors and interactions, improving the robustness of the transduction process.
  • Antha's DoE suite enabled rapid and flexible definition of automated liquid handling protocols, enhancing experimental efficiency.
  • The use of Antha led to a more robust and reliable execution of experiments, achieving key optimization objectives within two weeks.
  • Oxford Biomedica could focus more on analysis and experimental planning, driving their R&D forward rather than on repetitive manual tasks.
数量效益
  • 3 to 10-fold increase in vector titre upon transduction
  • 81% reduction in pure error
  • Up to 40 hours time saving on experimental planning and execution
  • 95-98% time saving in workflow setup and optimization
  • 22% saving in liquid handling actions

Case Study missing?

Start adding your own!

Register with your work email and create a new case study profile for your business.

Add New Record

相关案例.

联系我们

欢迎与我们交流!
* Required
* Required
* Required
* Invalid email address
提交此表单,即表示您同意 IoT ONE 可以与您联系并分享洞察和营销信息。
不,谢谢,我不想收到来自 IoT ONE 的任何营销电子邮件。
提交

感谢您的信息!
我们会很快与你取得联系。